Welcome

OWL is a biotechnology company in the field of Metabolomics with pioneering diagnostics products and unique R&D services for the scientific community.

Metabolomics uncovers metabolic alterations in biological samples and provides an overall picture of human or animal health: The information on complex biochemical processes obtained is highly valuable in drug mechanism and toxicology studies, biomarker discovery and the optimization of biotechnological processes.

OWL´s two business lines stem from our in depth knowledge of metabolomics and liver diseases.

DIAGNOSTIC PRODUCTS:

"OWLiver Test" is the first "in vitro" test for determining steatosis and NASH.
The company also develops diagnostic markers research for high prevalence diseases.

R&D SERVICES:

OWL applies its expertise in metabolomics and lipidomics to provide services to the pharmaceutical, food and cosmetics industries, as well as research centers, biotech companies and CROs.

 

Company introduction

  • OWLiver - information for physicians - how it works
  • owl liver for patients - that is it - benefits - faqs
  • what is metabolomics - get to know owl technology
Events
News

12/02/2016

News

CONVOCATORIA DE LA JUNTA GENERAL EXTRAORDINARIA DE SOCIOS DE ONE WAY LIVER, S.L.

 

12/01/2016

News

OWL Metabolomics in the front row of NASH and NAFLD non-invasive diagnosis.
OWL Metabolomics strengthens its position in NASH and NAFLD non-invasive diagnosis during The AASLD Liver Meeting®, the main worldwide meeting for the hepatology community, which took place in Boston from November 10th to 14th.

 

10/20/2016

News

OWL Metabolomics will be presenting new data related to innovations in NASH and NAFLD non-invasive diagnosis in clinical practice and the subtyping of NAFLD severity through metabolomics at the upcoming AASLD Liver Meeting® 2016.
OWL´s latest presentations at The AASLD Liver Meeting will consist on an oral communication and two posters. OWL will also be present at AASLD with a corporate display in the commercial exhibit space. Please plan on visiting OWL in Booth #638 during The Liver Meeting.

 

09/21/2016

News

NuSirt Biopharma and OWL Metabolomics Partner to Advance Treatment of NASH / Non-alcoholic Steatohepatitis
Through their research collaboration, NuSirt and OWL will evaluate drug-induced lipidomic changes in human trials for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) and explore the potential of developing a unique liquid-biopsy companion diagnostic (CDx) for NS-0200.

 

OWL is a trading name of
ONE WAY LIVER, S.L
Parque Tecnológico de Bizkaia
Edificio 502 - Planta 0
48160 Derio - Bizkaia - Spain
Phone: +34 94 431 85 40
Fax: +34 94 431 71 40

With this web OWL intends to provide users with information to better understand their health and their diagnosed illnesses. You should consult with a
qualified physician for diagnosis and for answers to your personal questions/circunstances.
Last update: 12/02/2016

With the collaboration of: